Risk of Type 2 Diabetes After Breast Cancer Treatment: a Population-based Cohort Study in Denmark

Overview

Journal J Natl Cancer Inst

Publisher Oxford University Press

Specialty Oncology

Date 2024 Oct 22

PMID 39436974

Authors

Kasper A Kjaergaard

Astrid Kousholt

Reimar W Thomsen

Kirsten M Woolpert

Henrik T Sorensen

Signe Borgquist

Deirdre Cronin-Fenton

Affiliations

Soon will be listed here.

Abstract

Purpose: Data on type 2 diabetes (T2D) risk after breast cancer (BC) could guide preventive strategies. Yet, studies had limitations regarding sample size, follow-up, and contemporary treatments. We evaluated the risk of T2D after BC overall, by cancer treatment, and compared with a matched cohort of cancer-free women.

Methods: We assembled a population-based cohort of early-stage BC patients aged 30 years or more diagnosed during 1996-2021 in Denmark. We created a comparison cohort of 5 cancer- and T2D-free women for each BC patient, matched 6 months after BC diagnosis date on age and region. We followed both cohorts until T2D diagnosis, emigration, death, or December 31, 2022. We computed 5-year cumulative incidences and used Cox models to calculate time-varying adjusted hazard ratios (aHR) of T2D.

Results: Among 74 526 BC survivors and 372 630 matched cancer-free women, 5-year cumulative incidences of T2D were 3.8% (95% confidence interval [CI] = 3.7 to 3.9) and 3.3% (95% CI = 3.3 to 3.4), respectively. The aHR of T2D was elevated but attenuated over follow-up (aHR5-years = 1.20, 95% CI = 1.15 to 1.25, and aHR15-years = 1.09, 95% CI = 1.05 to 1.12). Adjuvant endocrine therapy (aHR = 1.14; 95% CI = 1.10 to 1.19), aromatase inhibitors (aHR = 1.25; 95% CI = 1.18 to 1.32), and less so tamoxifen (aHR = 1.05; 95% CI = 0.99 to 1.11), were associated with elevated risk of T2D in women with BC vs cancer-free women. Among BC patients, chemotherapy (aHR = 1.10, 95% CI = 1.03 to 1.17) and radiation therapy (right-sided aHR = 1.18, 95% CI = 1.09 to 1.27 and left-sided aHR = 1.24, 95CI = 1.15 to 1.33) were associated with increased T2D risk.

Conclusion: BC was associated with excess risk of T2D, although of lower magnitude than previously reported. The excess risk was temporary and related to BC treatment but could also be influenced by obesity and heightened T2D diagnostic activity.

References

Solmunde E, Falstie-Jensen A, Lorenzen E, Ewertz M, Reinertsen K, Dekkers O . Breast cancer, breast cancer-directed radiation therapy and risk of hypothyroidism: A systematic review and meta-analysis. Breast. 2023; 68:216-224. PMC: 9996441. DOI: 10.1016/j.breast.2023.02.008. View

Wang C, Shih S, Huang K . Increasing risk of diabetes mellitus in postmenopausal women with newly diagnosed primary breast cancer. J Diabetes Investig. 2019; 11(2):490-498. PMC: 7078077. DOI: 10.1111/jdi.13112. View

Lipscombe L, Fischer H, Yun L, Gruneir A, Austin P, Paszat L . Association between tamoxifen treatment and diabetes: a population-based study. Cancer. 2011; 118(10):2615-22. DOI: 10.1002/cncr.26559. View

Choi Y, Bak K, Yeo Y, Choi Y, Shin S . Incident Type 2 Diabetes Risk of Selective Estrogen Receptor Modulators in Female Patients with Breast Cancer. Pharmaceuticals (Basel). 2021; 14(9). PMC: 8472249. DOI: 10.3390/ph14090925. View

Thomas N, Scalzo R, Wellberg E . Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy. Nat Rev Endocrinol. 2023; 20(1):16-26. PMC: 11487546. DOI: 10.1038/s41574-023-00899-0. View

Rillamas-Sun E, Kwan M, Iribarren C, Cheng R, Neugebauer R, Rana J . Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer. Breast Cancer Res Treat. 2023; 201(1):117-126. PMC: 10498727. DOI: 10.1007/s10549-023-06997-x. View

Darby S, Ewertz M, McGale P, Bennet A, Blom-Goldman U, Bronnum D . Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013; 368(11):987-98. DOI: 10.1056/NEJMoa1209825. View

Moller S, Jensen M, Ejlertsen B, Bjerre K, Larsen M, Hansen H . The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol. 2008; 47(4):506-24. DOI: 10.1080/02841860802059259. View

Tsilidis K, Kasimis J, Lopez D, Ntzani E, Ioannidis J . Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015; 350:g7607. DOI: 10.1136/bmj.g7607. View

10.

Gribsholt S, Pedersen L, Richelsen B, Thomsen R . Validity of ICD-10 diagnoses of overweight and obesity in Danish hospitals. Clin Epidemiol. 2019; 11:845-854. PMC: 6748036. DOI: 10.2147/CLEP.S214909. View

11.

Le May C, Chu K, Hu M, Ortega C, Simpson E, Korach K . Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci U S A. 2006; 103(24):9232-7. PMC: 1482595. DOI: 10.1073/pnas.0602956103. View

12.

Kwan M, Cheng R, Iribarren C, Neugebauer R, Rana J, Nguyen-Huynh M . Risk of Cardiometabolic Risk Factors in Women With and Without a History of Breast Cancer: The Pathways Heart Study. J Clin Oncol. 2022; 40(15):1635-1646. PMC: 9113213. DOI: 10.1200/JCO.21.01738. View

13.

Hernan M . The hazards of hazard ratios. Epidemiology. 2009; 21(1):13-5. PMC: 3653612. DOI: 10.1097/EDE.0b013e3181c1ea43. View

14.

Gurney J, Stanley J, Teng A, Krebs J, Koea J, Lao C . Cancer and diabetes co-occurrence: A national study with 44 million person-years of follow-up. PLoS One. 2022; 17(11):e0276913. PMC: 9704677. DOI: 10.1371/journal.pone.0276913. View

15.

Banerjee A, Chitnis U, Jadhav S, Bhawalkar J, Chaudhury S . Hypothesis testing, type I and type II errors. Ind Psychiatry J. 2010; 18(2):127-31. PMC: 2996198. DOI: 10.4103/0972-6748.62274. View

16.

Greenlee H, Iribarren C, Rana J, Cheng R, Nguyen-Huynh M, Rillamas-Sun E . Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study. J Clin Oncol. 2022; 40(15):1647-1658. PMC: 9113215. DOI: 10.1200/JCO.21.01736. View

17.

Storm H, Michelsen E, Clemmensen I, Pihl J . The Danish Cancer Registry--history, content, quality and use. Dan Med Bull. 1997; 44(5):535-9. View

18.

Carstensen B, Ronn P, Jorgensen M . Prevalence, incidence and mortality of type 1 and type 2 diabetes in Denmark 1996-2016. BMJ Open Diabetes Res Care. 2020; 8(1). PMC: 7265004. DOI: 10.1136/bmjdrc-2019-001071. View

19.

Urbute A, Frederiksen K, Kjaer S . Early adulthood overweight and obesity and risk of premenopausal ovarian cancer, and premenopausal breast cancer including receptor status: prospective cohort study of nearly 500,000 Danish women. Ann Epidemiol. 2022; 70:61-67. DOI: 10.1016/j.annepidem.2022.03.013. View

20.

Harborg S, Cronin-Fenton D, Jensen M, Ahern T, Ewertz M, Borgquist S . Obesity and Risk of Recurrence in Patients With Breast Cancer Treated With Aromatase Inhibitors. JAMA Netw Open. 2023; 6(10):e2337780. PMC: 10576219. DOI: 10.1001/jamanetworkopen.2023.37780. View